“Recently, studies in humans and preclinical models have found associations between alterations in the gut microbiome and the metabolic/clinical features of PCOS.
It is theorized that gut dysbiosis could be a pathogenetic factor in PCOS. Accordingly, changing the gut microbiome using probiotics, prebiotics, and synbiotics as well as diet may serve as a new therapeutic modality for PCOS. Specific changes of the gut microbiome in women with PCOS are apparently associated with distinct PCOS phenotypes. Several recent studies indicate that IR, sex steroid concentrations, and obesity alter the quantity, diversity and species composition of gut bacteria in women with PCOS (and vice versa)…
…Certain drugs, chiefly those used to treat obesity, prediabetes, and T2DM are known to alter the gut biome favorably, while others, the best known of which are antibiotics, may cause dysbiosis with unfavorable metabolic consequences [51, 52, 53]. Among the drugs with beneficial gut biome effects which explain at least part of their clinical actions are metformin, the alpha-glucosidase inhibitors, the GLP-1 receptor agonists, and the dual GLP-1/GLP-2 receptor agonist, tirzepatide.”
– See https://www.intechopen.com/chapters/79975
Rare and Underappreciated Causes of Polycystic Ovarian Syndrome
November 2021, Polycystic Ovary Syndrome